List of Excipients in Branded Drug LEUKINE

LEUKINE Excipient Strategy and Commercial Opportunities: Sargramostim Formulation, IP, and Market Analysis

Last updated: October 2, 2026

LEUKINE is a recombinant human granulocyte-macrophage colony-stimulating factor containing sargramostim. Its commercial formulation uses a relatively simple excipient system built around mannitol, sucrose, tromethamine, and methionine. The main opportunity is not a broad excipient substitution strategy. It is the development of differentiated, ready-to-use, stable, low-burden sargramostim presentations that reduce reconstitution steps, support outpatient administration, and improve storage and transport economics.

LEUKINE is marketed by Partner Therapeutics in the United States. It is regulated as a biologic under Biologics License Application No. 103919. Its principal competitive risks come from alternative granulocyte-colony stimulating factors, hospital formulary substitution, and potential future sargramostim biosimilars rather than from conventional small-molecule generics.[1,2]

What excipients are used in LEUKINE?

The labeled LEUKINE formulation contains mannitol, sucrose, tromethamine, and methionine. The product is supplied in both lyophilized and liquid presentations, subject to product-specific labeling and availability.[1]

Excipient	Primary formulation role	Commercial relevance
Mannitol	Bulking agent and tonicity modifier	Supports lyophilized cake structure and osmotic balance
Sucrose	Stabilizer and cryoprotectant	Protects the recombinant protein during freezing, drying, and storage
Tromethamine	Buffering agent	Helps maintain formulation pH during storage and administration
Methionine	Oxidation-control excipient	Limits oxidative degradation of the protein
Water for injection	Diluent in liquid presentation or reconstitution medium	Determines handling and administration requirements

The absence of a conventional antimicrobial preservative is commercially relevant. LEUKINE is supplied as a single-dose product, which avoids the need to balance preservative efficacy against protein aggregation, local tolerability, and regulatory complexity.[1]

The excipient system is consistent with common stabilization approaches for recombinant proteins. Sucrose provides preferential hydration and protects the protein structure during lyophilization. Mannitol improves the physical structure of the dried product but can crystallize under some processing conditions, making the mannitol-to-sucrose ratio and drying cycle important to product performance. Methionine is used as a sacrificial oxidation substrate, while tromethamine controls pH.

How does the LEUKINE formulation work from a stability perspective?

The formulation strategy addresses four principal degradation pathways: aggregation, oxidation, deamidation, and loss of activity during freeze-drying or reconstitution.

Lyophilized formulation

The lyophilized presentation offers several commercial advantages:

• Greater tolerance for distribution outside tightly controlled refrigerated channels.
• Lower sensitivity to accidental short-term temperature excursions.
• Longer potential shelf life than an equivalent liquid formulation, subject to validated stability data.
• Reduced risk of transport-related agitation damage.
• Suitability for institutions that can reconstitute injectable biologics before use.

The principal disadvantages are operational. Healthcare personnel must reconstitute the product, inspect the solution, and comply with administration and in-use handling requirements. Reconstitution introduces preparation time, potential dosing error, and a risk of delayed administration in urgent treatment settings.

Liquid formulation

A liquid presentation can remove the reconstitution step and support faster administration. It is more compatible with centralized pharmacy workflows, outpatient infusion centers, emergency preparedness stockpiles, and home-care models if the route, dose, packaging, and storage requirements permit.

The commercial trade-off is greater sensitivity to:

• Protein aggregation during long-term storage.
• Oxidation and chemical degradation.
• Freeze-thaw exposure.
• Container-closure interaction.
• Silicone oil or tungsten-related particulates in prefilled syringe systems.
• Shipping vibration and temperature excursions.

For sargramostim, the liquid formulation opportunity is therefore a balance between convenience and stability. A successful differentiated product would need to demonstrate meaningful operational advantages without introducing a material loss of shelf life or a higher cold-chain burden.

What formulation patents protect LEUKINE?

Publicly available product information identifies the approved composition and manufacturing controls but does not establish that the marketed excipient combination is protected by a currently enforceable, product-specific formulation patent. The core commercial protection for LEUKINE historically has rested more heavily on biologic regulatory approval, manufacturing know-how, clinical data, and method-of-use rights than on a single excipient patent.

A patent review should separate four categories:

Patent category	Relevance to LEUKINE	Commercial impact
Sargramostim composition patents	May cover protein sequence, expression construct, or host-cell production	Generally limited by expiration and claim scope
Formulation patents	May cover stabilizer ratios, pH, concentration, liquid stability, or lyophilization	Could delay or complicate follow-on entry
Method-of-use patents	May cover AML, progenitor-cell mobilization, transplantation, or radiation injury	Can support indication-specific litigation
Manufacturing patents	May cover cell culture, purification, refolding, or quality-control processes	Can raise biosimilar development costs

The relevant legal question is not whether mannitol, sucrose, tromethamine, or methionine is individually patentable. Those excipients are established pharmaceutical ingredients. The question is whether a valid claim covers a specific combination, concentration range, pH, processing condition, container system, or stability result that is difficult to design around.

Because LEUKINE is a biologic, Orange Book analysis does not apply in the same way as it does for small-molecule drugs. Biologic regulatory exclusivity and patent information are assessed through the Purple Book and the applicable biologics framework, including the Biologics Price Competition and Innovation Act.[2,3]

What is the FDA regulatory status of LEUKINE?

LEUKINE is an FDA-approved sargramostim biologic marketed in injectable form. Its approved uses include hematopoietic progenitor-cell mobilization, recovery of myeloid cells after specified chemotherapy or transplantation settings, and treatment of hematopoietic syndrome associated with acute radiation syndrome.[1]

Regulatory element	LEUKINE status
Active ingredient	Sargramostim
Product class	Recombinant human GM-CSF
FDA pathway	Biologics License Application
BLA	103919
Dosage forms	Lyophilized powder and liquid injectable presentations
Administration	Subcutaneous or intravenous, depending on indication and labeling
Orange Book listing	Not the primary biologic reference framework
Purple Book relevance	Yes
Biosimilar pathway	Potentially available under section 351(k)
Preservative strategy	Single-dose, preservative-free approach is commercially relevant

The formulation and presentation are part of the approved biologic product profile. A follow-on sponsor cannot assume that matching the active protein alone will provide equivalent commercial usability. The sponsor must address analytical comparability, product-related impurities, potency, aggregation, glycosylation, immunogenicity risk, and administration characteristics under the 351(k) pathway.[3,4]

When does LEUKINE lose exclusivity?

LEUKINE’s practical exclusivity position depends on several separate dates:

1. Regulatory exclusivity associated with the approved biologic.
2. Expiration of composition, formulation, manufacturing, and method-of-use patents.
3. The timing of any biosimilar application and FDA approval.
4. Litigation under the Biologics Price Competition and Innovation Act.
5. Commercial launch provisions in a settlement agreement.

The relevant reference product exclusivity period for a licensed biologic is generally 12 years from first licensure, subject to statutory rules and product-specific determinations. Pediatric exclusivity can add six months when applicable.[3]

A precise current loss-of-exclusivity date cannot be assigned solely from the trade name. Different patents can expire at different times, and a patent covering one indication or formulation may not block all competing uses. The commercial entry date can therefore differ from the earliest patent expiration date.

Which companies are challenging LEUKINE?

No broad, established field of commercial sargramostim biosimilars comparable to the filgrastim or pegfilgrastim markets has been identified in the principal FDA product databases. Competitive pressure is more visible from alternative products than from direct sargramostim copies.

Direct and indirect competitors

Competitor	Active ingredient	Primary commercial position
LEUKINE	Sargramostim	GM-CSF with broad hematopoietic and radiation-injury uses
Neupogen	Filgrastim	G-CSF with extensive oncology and neutropenia use
Zarxio	Filgrastim-sndz	Biosimilar filgrastim
Nivestym	Filgrastim-aafi	Biosimilar filgrastim
Granix	Tbo-filgrastim	Long-acting or alternative G-CSF positioning depending on use
Neulasta and biosimilars	Pegfilgrastim products	Once-per-cycle neutrophil support
Mozobil	Plerixafor	Mobilization adjunct rather than direct cytokine substitute

Sargramostim and filgrastim are not interchangeable from a clinical, regulatory, or formulary perspective. Sargramostim acts through the GM-CSF receptor and has broader myeloid, monocyte, and dendritic-cell effects. Filgrastim acts primarily through the G-CSF receptor and has a different efficacy, toxicity, dosing, and evidence profile.[1,5]

What commercial opportunities exist for LEUKINE excipient innovation?

The strongest opportunities involve usability, stability, and distribution rather than replacing the entire excipient system.

1. Extended-stability liquid sargramostim

A liquid product with longer refrigerated stability, broader temperature tolerance, or limited room-temperature exposure could reduce pharmacy waste and improve emergency stockpile economics.

Potential differentiators include:

• Lower aggregate formation.
• Lower particulate burden.
• Longer post-puncture in-use period.
• Reduced sensitivity to freeze-thaw events.
• Compatible prefilled syringe or autoinjector presentation.
• Lower protein concentration if dose volume remains clinically practical.

The development risk is high because liquid biologics require extensive stability characterization. A new liquid formulation may also trigger comparability and clinical bridging questions if it changes concentration, excipient levels, route, device, or pharmacokinetic behavior.

2. Ready-to-use hospital presentation

A ready-to-administer vial, cartridge, or pharmacy-ready syringe could reduce preparation labor and medication errors. This is relevant in transplant centers, oncology clinics, and public-health preparedness programs.

The commercial value increases if the presentation supports:

• Barcode medication administration.
• Dose preparation without manual dilution.
• Low residual volume.
• Clear visual inspection.
• Automated pharmacy compounding workflows.
• Reduced occupational exposure during preparation.

The main barrier is container-closure development. Protein adsorption, silicone oil, extractables, leachables, and particulate control become more important in a prefilled or wearable system.

3. Low-volume or concentrated formulation

A more concentrated sargramostim formulation could reduce injection volume and improve subcutaneous tolerability. This strategy requires careful evaluation of viscosity, local irritation, aggregation, and dose accuracy.

The commercial case is strongest for outpatient use and repeated dosing. A concentrated presentation would have limited value if the relevant indication is administered predominantly in controlled inpatient settings.

4. Alternative sugar or amino-acid systems

Trehalose, arginine, histidine, glycine, or other established stabilizers could be evaluated as alternatives or complements to sucrose, mannitol, tromethamine, and methionine. These changes may improve specific stability attributes but do not automatically create a strong patent position.

The most defensible IP would likely require a defined formulation window linked to a measurable technical result, such as:

• Reduced high-molecular-weight species.
• Improved potency retention.
• Lower subvisible particle formation.
• Improved recovery after reconstitution.
• Longer stability under temperature excursion.
• Reduced adsorption to the delivery device.

A broad claim to an excipient such as sucrose or methionine would face significant prior-art pressure. Narrow, performance-linked claims are more realistic.

What manufacturing and IP barriers affect a LEUKINE follow-on?

A sargramostim follow-on program would face several technical barriers:

Protein expression and glycosylation

Sargramostim is a recombinant protein. The expression system can affect glycosylation, charge variants, aggregation, host-cell proteins, and potency. These differences must be characterized against the reference product.

Biological activity

Analytical similarity must include a relevant cell-based potency assay. A sponsor cannot rely solely on mass spectrometry or binding assays if functional activity is central to the product’s clinical effect.

Formulation comparability

Changes in excipient identity, concentration, pH, or concentration can influence:

• Protein conformation.
• Aggregation.
• Deamidation.
• Oxidation.
• Reconstitution time.
• Injection-site tolerability.
• Immunogenicity risk.

Container and delivery system

The vial, stopper, syringe, needle, and administration device can affect extractables, leachables, adsorption, particulates, and delivered dose. A device-based differentiation strategy may provide a stronger commercial barrier than a basic excipient substitution.

Manufacturing know-how

Even where composition patents have expired, proprietary cell culture, purification, viral clearance, release testing, and stability protocols can raise development costs. These trade secrets may not appear in public patent databases but can materially affect time to approval and product consistency.

How does LEUKINE compare with filgrastim and pegfilgrastim?

Factor	LEUKINE	Filgrastim	Pegfilgrastim
Growth factor	GM-CSF	G-CSF	Pegylated G-CSF
Typical commercial role	Myeloid recovery, mobilization, radiation injury	Neutrophil recovery and prevention of febrile neutropenia	Once-per-cycle neutrophil support
Dosing frequency	Often daily or indication-specific	Often daily	Usually once per chemotherapy cycle
Biosimilar competition	Limited visible competition	Established	Established and expanding
Formulation opportunity	Liquid stability, ready-to-use delivery, stockpile presentation	Cost and device competition	Device, dose timing, and price competition
Differentiation basis	Mechanism, indications, formulation convenience	Price, interchangeability, supply	Convenience and reduced administration burden

LEUKINE’s commercial position depends on indications in which GM-CSF provides a clinically relevant benefit over G-CSF, not simply on lower acquisition cost. Formulation innovation can strengthen that position by reducing administration burden, but it is unlikely to overcome a substantial clinical or formulary preference for G-CSF products on price alone.

What generic launch risks exist for LEUKINE?

A conventional ANDA generic launch is not the expected pathway for sargramostim because LEUKINE is a biologic. A competing product would more likely proceed through a biosimilar or interchangeable biosimilar pathway under section 351(k).[3]

The principal launch scenarios are:

Scenario	Commercial effect
No approved biosimilar	LEUKINE retains broad reference-product pricing power, subject to therapeutic substitution
Non-interchangeable biosimilar	Contracting and physician adoption determine uptake
Interchangeable biosimilar	Pharmacy-level substitution could accelerate erosion where permitted
Improved liquid or device product	May preserve premium pricing despite protein similarity
Indication-specific patent settlement	Can delay or segment competitive entry
Hospital purchasing pressure	Can reduce net price before formal biosimilar launch

Method-of-use patents can complicate entry for specific indications. A biosimilar sponsor may seek approval for some uses while carving out patented methods, depending on applicable patent claims and labeling strategy. Settlement agreements can establish a negotiated launch date earlier than the latest asserted patent expiration.

What is the revenue exposure for LEUKINE?

Partner Therapeutics does not provide the same level of standalone public revenue reporting as a large publicly traded pharmaceutical company. Public filings therefore do not provide a consistently reported LEUKINE revenue figure suitable for a precise valuation model.

Revenue exposure is concentrated in:

• Oncology and hematology treatment centers.
• Hematopoietic progenitor-cell mobilization.
• Transplant programs.
• Acute radiation syndrome preparedness.
• Government or institutional procurement.
• Specialty distribution and hospital contracting.

The product’s revenue sensitivity is likely to differ by indication. Routine oncology use faces substitution and budget pressure from G-CSF products. Acute radiation syndrome procurement is more dependent on government preparedness and stockpiling decisions. Transplant and mobilization use depends on clinical protocols, institutional preference, and comparative use of plerixafor or G-CSF-based regimens.

How strong is the LEUKINE patent estate?

The commercial strength of the estate should be assessed as moderate rather than assumed to be strong solely because the product remains marketed.

Strengths include:

• Biologic manufacturing complexity.
• Clinical and regulatory data.
• Multiple approved uses.
• Potential formulation and process know-how.
• Specialized institutional distribution.
• Limited direct sargramostim competition.

Constraints include:

• Age of the product and likely maturity of core composition rights.
• Publicly known excipient system using established ingredients.
• Availability of alternative cytokine products.
• Potential biosimilar development under section 351(k).
• Difficulty using broad excipient claims to block design-around products.

The most valuable surviving protection would be a narrow, enforceable claim that covers the marketed liquid formulation, a critical stability range, a delivery device, a specific manufacturing process, or an important method of use.

Key Takeaways

• LEUKINE contains sargramostim and uses mannitol, sucrose, tromethamine, and methionine as its core excipient system.
• The formulation is designed to stabilize a recombinant protein through lyophilization, storage, reconstitution, and injection.
• The strongest commercial opportunity is a ready-to-use or more stable liquid presentation, not a simple excipient swap.
• A concentrated formulation, prefilled device, or lower-burden hospital presentation could support product differentiation.
• LEUKINE is a biologic, so biosimilar analysis under the 351(k) pathway is more relevant than conventional generic analysis.
• Orange Book listing analysis does not provide the primary exclusivity framework for LEUKINE.
• Direct sargramostim biosimilar competition appears less developed than filgrastim and pegfilgrastim competition.
• Manufacturing know-how, protein comparability, container closure, and potency testing are material barriers to follow-on entry.
• No precise standalone LEUKINE revenue estimate can be derived from public company reporting.
• Formulation patent strength depends on narrow, technically supported claims rather than ownership of common excipients.

FAQs

Can LEUKINE be reformulated without changing its regulatory status?

A material change to excipient composition, concentration, pH, dosage strength, container, device, or storage condition would generally require regulatory assessment and may require a supplement or a new application, depending on the change and its effect on product quality.

Could a preservative-containing sargramostim product compete with LEUKINE?

It could be technically feasible, but a preservative may create tolerability, protein stability, immunogenicity, and regulatory burdens. A single-dose preservative-free product may remain commercially preferable for biologic injection.

Is a sargramostim biosimilar likely to use the same excipients as LEUKINE?

Not necessarily. A biosimilar sponsor may use the same excipients to reduce comparability risk or select a different system to improve stability, manufacturing yield, or device compatibility.

Which excipient is most important for LEUKINE stability?

Sucrose is likely to be central to protein stabilization during lyophilization and storage, while methionine addresses oxidative degradation and mannitol supports the physical structure of the dried product. The overall system, including pH and processing conditions, determines performance.

Could a new LEUKINE formulation obtain separate patent protection?

Yes. Patentability may exist for a defined excipient combination, concentration range, pH window, manufacturing process, container system, or stability result, provided the claims satisfy novelty, non-obviousness, enablement, and written-description requirements.

References

1. U.S. Food and Drug Administration. (2024). LEUKINE (sargramostim) prescribing information. Partner Therapeutics, Inc.

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

3. Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003, 124 Stat. 119, 804-821.

4. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. https://www.fda.gov/

5. National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Hematopoietic growth factors. NCCN.